

# Caroline H Williams-Gray

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11477354/publications.pdf>

Version: 2024-02-01

41  
papers

6,686  
citations

159585

30  
h-index

289244

40  
g-index

43  
all docs

43  
docs citations

43  
times ranked

6644  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: <i>Movement</i> Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012, 27, 349-356.	3.9	1,908
2	The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. <i>Brain</i> , 2009, 132, 2958-2969.	7.6	842
3	The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1258-1264.	1.9	534
4	Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. <i>Brain</i> , 2017, 140, 3191-3203.	7.6	323
5	Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. <i>Brain</i> , 2013, 136, 392-399.	7.6	266
6	Tau and $\alpha$ -synuclein in susceptibility to, and dementia in, Parkinson's disease. <i>Annals of Neurology</i> , 2007, 62, 145-153.	5.3	256
7	Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. <i>Annals of Neurology</i> , 2016, 80, 674-685.	5.3	226
8	The natural history of treated Parkinson's disease in an incident, community based cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1112-1118.	1.9	200
9	Catechol-O-Methyltransferase val <sup>158</sup> met Genotype Influences Frontoparietal Activity during Planning in Patients with Parkinson's Disease. <i>Journal of Neuroscience</i> , 2007, 27, 4832-4838.	3.6	175
10	Attentional control in Parkinson's disease is dependent on COMT val158met genotype. <i>Brain</i> , 2008, 131, 397-408.	7.6	165
11	Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's Disease. <i>Journal of Neurology</i> , 2009, 256, 493-498.	3.6	141
12	The clinical heterogeneity of Parkinson's disease and its therapeutic implications. <i>European Journal of Neuroscience</i> , 2019, 49, 328-338.	2.6	137
13	Cognitive decline and quality of life in incident Parkinson's disease: The role of attention. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 47-53.	2.2	133
14	Prediction of cognition in Parkinson's disease with a clinical genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology</i> , The, 2017, 16, 620-629.	10.2	131
15	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. <i>Movement Disorders</i> , 2019, 34, 1839-1850.	3.9	122
16	Cognitive Deficits and Psychosis in Parkinson's Disease. <i>CNS Drugs</i> , 2006, 20, 477-505.	5.9	115
17	Genetic risk of Parkinson disease and progression. <i>Neurology: Genetics</i> , 2019, 5, e348.	1.9	109
18	Genomewide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 424-433.	3.9	101

#	ARTICLE	IF	CITATIONS
19	The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. <i>Movement Disorders</i> , 2017, 32, 510-525.	3.9	92
20	Stability of mild cognitive impairment in newly diagnosed Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 648-652.	1.9	88
21	Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. <i>Nature Genetics</i> , 2021, 53, 787-793.	21.4	82
22	Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 473-488.	4.1	58
23	Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. <i>Movement Disorders</i> , 2012, 27, 312-315.	3.9	56
24	Impact of <i>GBA1</i> variants on long-term clinical progression and mortality in incident Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 695-702.	1.9	48
25	The Genetic Basis of Cognitive Impairment and Dementia in Parkinson's Disease. <i>Frontiers in Psychiatry</i> , 2016, 7, 89.	2.6	46
26	<i>GBA1</i> and <i>APOE</i> Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study. <i>Movement Disorders</i> , 2022, 37, 1016-1027.	3.9	45
27	Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2550-2554.	3.9	44
28	Motor Complications in Parkinson's Disease: 13-Year Follow-up of the CamPAIGN Cohort. <i>Movement Disorders</i> , 2020, 35, 185-190.	3.9	39
29	Addenbrooke's Cognitive Examination-Revised for mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1173-1177.	3.9	38
30	Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinson's Disease: The ICICLE-PD Study. <i>Journal of Parkinson's Disease</i> , 2020, 10, 193-206.	2.8	34
31	Cerebrospinal Fluid Cytokines and Neurodegeneration-Associated Proteins in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1062-1066.	3.9	33
32	Inflammation in mild cognitive impairment due to Parkinson's disease, Lewy body disease, and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1244-1250.	2.7	31
33	Mild Cognitive Impairment and Parkinson's Disease - Something to Remember. <i>Journal of Parkinson's Disease</i> , 2015, 4, 651-656.	2.8	22
34	The motor and cognitive features of Parkinson's disease in patients with concurrent Gaucher disease over 2 years: a case series. <i>Journal of Neurology</i> , 2018, 265, 1789-1794.	3.6	11
35	Which Neuropsychological Tests? Predicting Cognitive Decline and Dementia in Parkinson's Disease in the ICICLE-PD Cohort. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1297-1308.	2.8	11
36	A common polymorphism in <i>SNCA</i> is associated with accelerated motor decline in <i>GBA1</i> -Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 673-674.	1.9	9

#	ARTICLE	IF	CITATIONS
37	No alterations in $\alpha$ -synuclein gene dosage observed in sporadic Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 731-732.	3.9	6
38	From Molecule to Clinic and Community for Neurodegeneration: Research to Bridge Translational Gaps. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S385-S396.	2.6	5
39	Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 250-251.	2.5	1
40	Neuropsychological Features of Early Cognitive Impairment in Parkinson's Disease. <i>Advances in Biological Psychiatry</i> , 2012, , 84-102.	0.2	1
41	The genetics of behavior and cognition in Parkinson's disease. , 0, , 25-39.		0